Urinary%20incontinence%20in%20women Patient Education

Patient Education

Lifestyle Modification

Fluid Intake

Average amount of fluid needed per day is calculated based on patient’s lean body mass
Encourage patients to modify their fluid intake to produce a 24-hour urinary output between 1-2 L

A very large or small urine volume output can contribute to UI

Diet

Certain foods contain stimulants that may exacerbate symptoms of incontinence
- Heavy or hot spices
- Fruits or juices with acidic pH
- Corn syrup, sugar, honey
Use of artificial sweeteners may also contribute to urge incontinence

Caffeine

Studies suggest that decreasing caffeine may improve frequency and urgency but not incontinence
Eg coffee, tea, carbonated drinks and hot chocolate

Weight Loss

Should be considered as 1st-line treatment for UI in overweight and obese women
In morbidly obese women, massive (surgically induced) weight loss has been shown to significantly decrease incontinence
- Moderate weight loss may also decrease incontinence

Smoking Cessation

Smoking >20 cigarettes per day is considered to reinforce UI

Use of Anti-incontinence Products

Pads and products that help contain urine loss may be beneficial
Absorbent products are temporary means to absorb urine and help protect skin and clothing

May also be used as adjunct to behavioral and pharmacological treatment
Patient may be assessed yearly for efficacy of the absorbent product and evaluation of skin integrity and quality of life

Catheters
- Eg intermittent or indwelling urethral or suprapubic bladder catheterization
- Discuss with the patient the risks and benefits of catheterization
- Some patients improve with temporary continuous Foley catheterization wherein bladder capacity returns to normal and voluntary detrusor function improves
- Intermittent self-catheterization is the best form of bladder draining for those who are not physically or mentally handicapped
Urethral occlusive products
- Artificial device inserted into or placed over urethral meatus
- Keep patients drier but more difficult and expensive to use compared to absorbent products
Intravaginal mechanical devices (eg incontinence pessaries) for select women may improve stress and mixed UI

Catheters

Product Highlight - Talzenna

13 Sep 2022

Talazoparib 0.25 mg hard cap

Management of recurrent implantation failure during the COVID-19 pandemic

Dr. Ameet Patki, Dr. Prakash Mayandi, 22 Mar 2022

Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.